Aditxt inc ADTX.US 總覽分析

美股醫療保健
(ADTX 無簡報檔)

ADTX 投資分析

看多重點：

  • 價值≥4
  • 股利≥2

分析結論

價值面評分低，若以價值投資為目標且有長期投資部位，需要嚴格執行自己的出場計畫來減持部位

ADTX 近期報酬表現

3.47%

Aditxt inc

4.57%

同產業平均

3.26%

S&P500

與 ADTX 同產業的標的表現

  • IBO Impact biomedical inc
    價值 -趨勢 2 分波段 4 分籌碼 -股利 1 分
    查看更多

ADTX 公司資訊

Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.

ADTX 股價